{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-051406","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2022-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.658512+00:00","generated_at":"2026-06-26T03:05:38.219990+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Innoviva Q1 royalties up 5% to $93.5M; invested $45M in Armata, $15M in Entasis","bullets":["Gross royalty revenues of $93.5M (+5% YoY); TRELEGY sales up 33% to $450.9M.","Issued $261M 2.125% convertible notes due 2028; repurchased $144.8M of 2023 notes.","Invested $45M in Armata for ~69% ownership; $15M convertible debt financing to Entasis.","Non-binding offer to acquire Entasis at $2.00/share; consolidated Entasis financials.","Net cash $183.3M (excl. $33.5M Entasis cash); receivables $93.5M from GSK."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-051406","json":"https://secwatch.observer/filing/0001104659-22-051406.json","markdown":"https://secwatch.observer/filing/0001104659-22-051406.md","text":"https://secwatch.observer/filing/0001104659-22-051406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000110465922051406/0001104659-22-051406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000110465922051406/tm2213783d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T03:05:38.219990+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}